MCID: WLL006
MIFTS: 59

Wells Syndrome malady

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Wells Syndrome

Aliases & Descriptions for Wells Syndrome:

Name: Wells Syndrome 50 56 69
Eosinophilic Cellulitis 50 56
Bullous Cellulitis with Eosinophilia 50
Wells' Syndrome 50

Characteristics:

Orphanet epidemiological data:

56
wells syndrome
Inheritance: Not applicable; Prevalence: <1/1000000 (Worldwide); Age of onset: Adult; Age of death: normal life expectancy;

Classifications:

Orphanet: 56  
Rare skin diseases


External Ids:

Orphanet 56 ORPHA901
MESH via Orphanet 43 C536693
UMLS via Orphanet 70 C0343101
ICD10 via Orphanet 34 L98.3
ICD10 33 L98.3

Summaries for Wells Syndrome

NIH Rare Diseases : 50 wells syndrome is a rare eosinophilic disorder that primarily affects the skin. affected people typically develop a skin rash that is often proceeded by itching or burning skin. the rash consists of raised, red, swollen areas that may be warm to the touch. the symptoms generally come on rapidly and may last four to eight weeks. in some cases, the rash may recur (occur frequently or repeatedly) for years. the exact underlying cause of wells syndrome is currently unknown; however, some scientists believe that it may be an autoimmune reaction. oral or topical corticosteroids are commonly used to treat wells syndrome, although antifungal drugs, antibiotics, immunosuppressants, and/or antihistamines have also been used with varying degrees of success. last updated: 4/27/2015

MalaCards based summary : Wells Syndrome, also known as eosinophilic cellulitis, is related to muckle-wells syndrome and hay-wells syndrome, and has symptoms including pruritus, cellulitis and edema. An important gene associated with Wells Syndrome is NLRP3 (NLR Family Pyrin Domain Containing 3), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Ethanol and Heparin have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and monocytes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and homeostasis/metabolism

CDC : 3 Many people in the United States receive their water from private ground water wells. EPA regulations that protect public drinking water systems do not apply to privately owned wells. As a result, owners of private wells are responsible for ensuring that their water is safe from contaminants. Here you may find information on the basics of wells, proper methods of siting and location for wells, all about testing and how often to test a well, proper treatment of wells and maintenance of wells , information on well retirement, common diseases and contaminants associated with wells, emergency treatment of wells, and answers to frequently asked questions about wells.

Wikipedia : 71 Eosinophilic cellulitis, also known as Wells\' syndrome, is a skin disease that presents with painful,... more...

Related Diseases for Wells Syndrome

Diseases related to Wells Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 161)
id Related Disease Score Top Affiliating Genes
1 muckle-wells syndrome 33.3 CASP1 IL1B IL1R1 MEFV NLRP3 TNFRSF1A
2 hay-wells syndrome 12.2
3 cryopyrin-associated periodic syndrome 10.8
4 familial cold-induced inflammatory syndrome 1 10.4
5 oligoarticular juvenile idiopathic arthritis with anti-nuclear antibodies 10.4 MEFV TNFRSF1A
6 spondylocostal dysostosis-hypospadias-intellectual disability syndrome 10.3 MEFV TNFRSF1A
7 pulmonary artery coming from the aorta 10.3 MEFV NLRP3
8 meier-gorlin syndrome 3 10.3 IL1B MEFV NLRP3
9 gonococcal endophthalmia 10.3 IL1B MEFV NLRP3
10 egg allergy 10.3 IL1B IL1R1 NLRP3
11 warthin tumor 10.3 IL1B IL1R1 NLRP3
12 cerebrum cancer 10.3 CRP IL1B TNFRSF1A
13 cutaneous sclerosis 10.3 CRP IL1R1 NLRP3
14 mechanical lagophthalmos 10.3 CRP MEFV TNFRSF1A
15 senile cataract 10.2 IL1B MEFV NLRP3 TP63
16 retinal cancer 10.2 CRP IL1B MEFV NLRP3
17 keratoconus 10.2 IL1B IL1R1 IL1RAPL2
18 patau syndrome 10.2 CRP IL1B MEFV TNFRSF1A
19 pancreas lymphoma 10.2 CRP IL1B MEFV TNFRSF1A
20 amelanotic melanoma 10.2 CASP1 IL1B NLRP3
21 tau syndrome 10.2 IL1B MEFV
22 skin conditions 10.2 CXCL8 IL1B NLRP3
23 neuropathy 10.2 CRP CXCL8 IL1B
24 benign neonatal seizures 10.2 CRP IL1B IL1R1 MEFV
25 atrophy of prostate 10.2 CRP CXCL8 IL1B
26 baritosis 10.2 CXCL8 IL1B NLRP3
27 blepharochalasis 10.2 CRP CXCL8 IL1B
28 chordoid meningioma 10.2 CRP CXCL8 IL1B
29 choroiditis 10.2 CRP CXCL8 IL1B
30 laryngotracheoesophageal cleft type 2 10.2 CRP IL1B IL2
31 histiocytoma 10.2 CXCL8 IL1R1 MEFV
32 infancy electroclinical syndrome 10.2 CRP CXCL8 IL1B
33 multinodular goiter 10.2 CRP IL2 NLRP3
34 unilateral hypoactive labyrinth 10.1 CRP CXCL8 IL1B
35 pyelonephritis 10.1 CRP CXCL8 IL1B
36 oculomotor nerve paralysis 10.1 CXCL8 IL1B
37 rift valley fever 10.1 CASP1 CRP IL1B
38 cellulitis 10.1
39 senile reticular retinal degeneration 10.1 CXCL8 IL1B IL1R1 NLRP3
40 hidradenitis 10.1 CRP CXCL8 IL1B MEFV
41 malignant histiocytosis 10.1 CXCL8 IL1R1 MEFV NLRP3
42 sclerosing adenosis of breast 10.1 CRP CXCL8 IL1B
43 retinitis pigmentosa 51 10.1 CRP CXCL8 RNASE3
44 amyotrophic lateral sclerosis type 14 10.1 CXCL8 IL1B IL2
45 synovium cancer 10.1 CRP CXCL8 IL1B
46 giant cell glioblastoma 10.1 CASP1 IL1B IL1R1 TNFRSF1A
47 foodborne botulism 10.1 CRP IL1B IL2 MEFV
48 coloboma of optic papilla 10.1 IL1R1 IL1RAPL2 NLRP3 RNASE3
49 chromophobe adenoma 10.1 CXCL8 IL2
50 uterine ligament clear cell adenocarcinoma 10.1 CRP CXCL8 IL1B

Graphical network of the top 20 diseases related to Wells Syndrome:



Diseases related to Wells Syndrome

Symptoms & Phenotypes for Wells Syndrome

Human phenotypes related to Wells Syndrome:

56 32 (show all 9)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pruritus 56 32 Very frequent (99-80%) HP:0000989
2 cellulitis 56 32 Very frequent (99-80%) HP:0100658
3 edema 56 32 Frequent (79-30%) HP:0000969
4 eosinophilia 56 32 Frequent (79-30%) HP:0001880
5 abnormal blistering of the skin 56 32 Frequent (79-30%) HP:0008066
6 skin vesicle 56 32 Frequent (79-30%) HP:0200037
7 fever 56 32 Occasional (29-5%) HP:0001945
8 arthralgia 56 32 Occasional (29-5%) HP:0002829
9 vasculitis 56 Excluded (0%)

GenomeRNAi Phenotypes related to Wells Syndrome according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 NLRP3 TNFRSF1A CASP1 CXCL8 IL1B IL2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 NLRP3 TNFRSF1A TP63 CASP1 CXCL8 IL1B

MGI Mouse Phenotypes related to Wells Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 TP63 MEFV NLRP3 RACK1 TNFRSF1A IL5
2 cellular MP:0005384 10.18 TNFRSF1A MEFV TP63 NLRP3 RACK1 HNRNPAB
3 immune system MP:0005387 10.15 TNFRSF1A MEFV TP63 NLRP3 IL5 IL1B
4 hematopoietic system MP:0005397 10.13 TNFRSF1A MEFV NLRP3 IL5 IL1B IL1R1
5 digestive/alimentary MP:0005381 10.06 TNFRSF1A TP63 NLRP3 IL5 CASP1 IL2
6 integument MP:0010771 9.97 TNFRSF1A MEFV TP63 NLRP3 RACK1 IL1B
7 liver/biliary system MP:0005370 9.8 TNFRSF1A MEFV NLRP3 IL5 IL1R1 IL2
8 neoplasm MP:0002006 9.76 TP63 TNFRSF1A IL5 IL1B IL1R1 CASP1
9 reproductive system MP:0005389 9.56 TNFRSF1A IL5 MEFV TP63 NLRP3 CASP1
10 respiratory system MP:0005388 9.17 TNFRSF1A TP63 IL5 IL1R1 IL2 FGFR2

Drugs & Therapeutics for Wells Syndrome

Drugs for Wells Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1261)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
2
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2 9005-49-6 772 46507594
3
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
4
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
6
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 69-65-8 453 6251
7
Heroin Approved, Illicit Phase 4 561-27-3 5462328
8
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
9
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
10
Zinc Approved Phase 4,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
11
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 104987-11-3 445643 439492
12
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
13
Indinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 150378-17-9 5362440
14
Loperamide Approved Phase 4 53179-11-6 3955
15
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154598-52-4 64139
16
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 51-43-4 5816
17
Nevirapine Approved Phase 4,Phase 3,Phase 2,Phase 1 129618-40-2 4463
18
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
19
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 1 59467-70-8 4192
20
Erythromycin Approved, Vet_approved Phase 4 114-07-8 12560
21
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
22
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1 30516-87-1 35370
23
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 24280-93-1 446541
24
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147127-20-6 464205
25
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128794-94-5 5281078
26
Acetaminophen Approved Phase 4,Phase 2,Phase 1,Early Phase 1 103-90-2 1983
27
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
28
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
29
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
30
Valsartan Approved, Investigational Phase 4,Phase 2 137862-53-4 60846
31
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
32
Amlodipine Approved Phase 4,Phase 3,Phase 2 88150-42-9 2162
33 Moxonidine Approved Phase 4 75438-57-2 4810
34
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
35
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-84-3 187
36
Memantine Approved, Investigational Phase 4,Phase 3 19982-08-2 4054
37
Didanosine Approved Phase 4,Phase 3,Phase 2,Phase 1 69655-05-6 50599
38
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 55-98-1 2478
39
Ribavirin Approved Phase 4,Phase 2,Phase 3,Phase 1 36791-04-5 37542
40
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
41
Ticlopidine Approved Phase 4,Phase 3,Phase 2 55142-85-3 5472
42
Tirofiban Approved Phase 4,Phase 3 144494-65-5 60947
43
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-23-7 5754 657311
44
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
45
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
46
Stavudine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 3056-17-5 18283
47
Fluoxetine Approved, Vet_approved Phase 4,Phase 2 54910-89-3 3386
48
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
49
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
50
Leuprolide Approved, Investigational Phase 4,Phase 2,Phase 3 53714-56-0 3911 657181

Interventional clinical trials:

(show top 50) (show all 3277)
id Name Status NCT ID Phase
1 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4
2 Low Dose Steroids in the Treatment of Nephrotic Syndrome Relapse Unknown status NCT02216747 Phase 4
3 Treatment of the Dumping Syndrome With Lanreotide Autogel® Unknown status NCT00543179 Phase 4
4 Close Kinect Chain Exercise With Kinesio Taping in the Management of Patellofemoral Pain Syndrome Unknown status NCT02241148 Phase 4
5 The Effects of Continuous Positive Airway Pressure on Overlap Syndrome Unknown status NCT00914264 Phase 4
6 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4
7 PROMAD: Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnea Unknown status NCT01532050 Phase 4
8 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4
9 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
10 CT Coronary Angiogram Versus Traditional Care in Emergency Department Assessment of Potential ACS Unknown status NCT00933400 Phase 4
11 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4
12 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4
13 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4
14 Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4
15 Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis Unknown status NCT02048085 Phase 4
16 Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease Unknown status NCT01383083 Phase 4
17 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
18 Once Daily 3TC, Efavirenz and ddI for HIV Infection Unknown status NCT00214435 Phase 4
19 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4
20 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
21 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4
22 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4
23 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Unknown status NCT00851942 Phase 4
24 Botulinum Toxin A for Treatment of Catocholamine Induced Finger Necrosis Unknown status NCT01500668 Phase 4
25 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
26 Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image Unknown status NCT01769482 Phase 4
27 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4
28 A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
29 Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes Unknown status NCT02236481 Phase 4
30 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4
31 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
32 Korean AMADEUS Study Unknown status NCT01239849 Phase 4
33 Evaluating Results of Neusidl Corneal Inserter in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) Unknown status NCT01357122 Phase 4
34 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4
35 Study of Fibromyalgia Treated With Milnacipran Unknown status NCT01125423 Phase 4
36 Simvastatin in Patients With Septic Shock Unknown status NCT00450840 Phase 4
37 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4
38 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4
39 Simplification From Protease Inhibitors to Raltegravir Unknown status NCT00941083 Phase 4
40 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
41 Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Unknown status NCT02404233 Phase 4
42 Pacing of the Atria in Sick Sinus Syndrome Trial Preventive Strategies for Atrial Fibrillation Completed NCT00161538 Phase 4
43 Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome Completed NCT01714011 Phase 4
44 Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome Completed NCT01118598 Phase 4
45 Improving the Management of Acute Coronary Syndromes in the Emergency Department Completed NCT01563250 Phase 4
46 Biseko Versus Albumin in Systemic Inflammatory Response Syndrome (SIRS) Patients Completed NCT00708747 Phase 4
47 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4
48 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed NCT01419249 Phase 4
49 Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome Post Marketing Commitment Study Completed NCT01668667 Phase 4
50 Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome Completed NCT00134745 Phase 4

Search NIH Clinical Center for Wells Syndrome

Genetic Tests for Wells Syndrome

Anatomical Context for Wells Syndrome

MalaCards organs/tissues related to Wells Syndrome:

39
Skin, Testes, Monocytes, T Cells, B Cells, Neutrophil, Myeloid

Publications for Wells Syndrome

Articles related to Wells Syndrome:

(show top 50) (show all 205)
id Title Authors Year
1
Placental Transfer of Canakinumab in a Patient with Muckle-Wells Syndrome. ( 28386702 )
2017
2
A Novel Mutation in the Pyrin Domain of the NOD-like Receptor Family Pyrin Domain Containing Protein 3 in Muckle-Wells Syndrome. ( 28229991 )
2017
3
Endometriosis in the setting of Muckle-Wells syndrome treated with an IL-1I^ antagonist. ( 28508753 )
2017
4
Wells syndrome. ( 27767278 )
2016
5
Wells' syndrome with a clinicopathological correlation associated with mantle-cell lymphoma. ( 26999270 )
2016
6
Muckle-Wells syndrome in Chinese patients: a single center case series. ( 28028683 )
2016
7
Treatment of eosinophilic cellulitis (Wells syndrome) - a systematic review. ( 27357601 )
2016
8
Muckle-Wells Syndrome: A Case Report with an NLRP3 T348M Mutation. ( 27435956 )
2016
9
Wells syndrome associated with chronic lymphocytic leukemia. ( 26375230 )
2015
10
Wells' Syndrome Mimicking Facial Cellulitis: A Report of Two Cases. ( 26120307 )
2015
11
Budget Impact Analysis of Canacinumab In The Treatment of Patients With Muckle-Wells Syndrome In The Russian Federation. ( 26533715 )
2015
12
Muckle-Wells syndrome: a rare hereditary cryopyrin-associated periodic syndrome. ( 26218404 )
2015
13
Idiopathic Hypereosinophilic Syndrome With Cutaneous Manifestations and Flame Figures: A Spectrum of Eosinophilic Dermatoses Whose Features Overlap With Wells' Syndrome. ( 25839890 )
2015
14
Early detection of sensorineural hearing loss in Muckle-Wells-syndrome. ( 26531310 )
2015
15
Muckle-Wells syndrome in an Indian family associated with NLRP3 mutation. ( 25766347 )
2015
16
Influenza Vaccination as a Novel Trigger of Wells Syndrome in a Child. ( 25894853 )
2015
17
Muckle wells syndrome associated with multifocal clinically isolated syndrome. ( 24618190 )
2014
18
Eosinophilic leukocytoclastic vasculitis - a spectrum ranging from Wells' syndrome to Churg-Strauss syndrome? ( 25115356 )
2014
19
Eosinophilic cellulitis (Wells' syndrome) caused by a temporary henna tattoo. ( 25395929 )
2014
20
Recurrent paraneoplastic wells syndrome in a patient with metastatic renal cell cancer. ( 24945651 )
2014
21
Life of Lesions in Eosinophilic Cellulitis (Wells' Syndrome)-A Condition That May Be Missed at First Sight. ( 25238447 )
2014
22
Wells syndrome: response to dapsone therapy. ( 25143695 )
2014
23
IgG4-related disease of the paratestis in a patient with Wells syndrome: a case report. ( 25487870 )
2014
24
Syndrome in question. Hay-Wells syndrome. ( 24770526 )
2014
25
Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1I^ monoclonal antibody canakinumab. ( 24510061 )
2014
26
Wells syndrome. ( 24505587 )
2014
27
Renal and thyroid amyloidosis secondary tocryopyrin-associated periodic syndrome(Muckle-Wells syndrome) (NLRP3 mutation). ( 23511763 )
2013
28
Persistent hypereosinophilia with Wells syndrome. ( 22607377 )
2013
29
Wells syndrome and its relationship to Churg-Strauss syndrome. ( 23786445 )
2013
30
Wells' syndrome associated with Churg-Strauss syndrome: correlation with mast cell distribution. ( 22998535 )
2013
31
Wells syndrome (eosinophilic cellulitis): Proposed diagnostic criteria and a literature review of the drug-induced variant. ( 24421864 )
2013
32
Muckle-Wells syndrome: a treatable cause of congenital sensorineural hearing loss. ( 23909124 )
2013
33
Eosinophilic annular erythema is a peculiar subtype in the spectrum of Wells syndrome: a multicentre long-term follow-up study. ( 22731886 )
2013
34
Hearing loss in Muckle-Wells syndrome. ( 23440695 )
2013
35
Challenges in diagnosing Muckle-Wells syndrome: Identifying two distinct phenotypes. ( 24127202 )
2013
36
Muckle-Wells syndrome without mutation in exon 3 of the NLRP3 gene, identified by evidence of excessive monocyte production of functional interleukin 1I^ and rapid response to anakinra. ( 23889084 )
2013
37
Chronic keratitis with intrastromal epithelioid histiocytes: a new finding in Muckle-Wells syndrome. ( 23187166 )
2013
38
Wells' syndrome associated with chronic myeloid leukaemia. ( 23147913 )
2013
39
Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes. ( 24326009 )
2013
40
Renal failure in Hay-Wells syndrome. ( 24231488 )
2013
41
Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. ( 23718630 )
2013
42
Muckle-Wells syndrome: individualized, reflare-guided dosing of the orphan drug canakinumab. ( 23745225 )
2013
43
Gigantic erythematous plaques with violaceous oedematous borders: a quiz. Wells' syndrome. ( 23572063 )
2013
44
Muckle-Wells syndrome and male hypofertility: a case series. ( 22512814 )
2012
45
Eosinophilic cellulitis (Wells syndrome) in a pediatric patient: a case report and review of the literature. ( 22611749 )
2012
46
Recurrent Wells' syndrome associated with allergic asthma exacerbation. ( 22035426 )
2012
47
Systemic lupus erythematosus associated with Wells' syndrome. ( 21340570 )
2012
48
Wells' syndrome presenting as a noninfectious bullous cellulitis in a child. ( 22409475 )
2012
49
Progressive familial hearing loss in Muckle-Wells syndrome. ( 22497426 )
2012
50
Idiopathic bullous eosinophilic cellulitis (Wells syndrome) responsive to topical tacrolimus and antihistamine combination. ( 22565446 )
2012

Variations for Wells Syndrome

Expression for Wells Syndrome

Search GEO for disease gene expression data for Wells Syndrome.

Pathways for Wells Syndrome

Pathways related to Wells Syndrome according to GeneCards Suite gene sharing:

(show all 40)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 CASP1 CRP CXCL8 FGFR2 IL1B IL1R1
2
Show member pathways
13.61 CASP1 CXCL8 FGFR2 IL1B IL1R1 IL2
3
Show member pathways
13.5 CXCL8 FGFR2 IL1B IL1R1 IL2 IL2RA
4
Show member pathways
13.36 CXCL8 FGFR2 IL1B IL1R1 IL2 IL2RA
5
Show member pathways
13.22 CASP1 CXCL8 FGFR2 IL1B IL1R1 IL2
6
Show member pathways
13.15 CASP1 CXCL8 FGFR2 IL1B IL1R1 IL2
7
Show member pathways
12.95 CASP1 CXCL8 IL1B IL1R1 MEFV NLRP3
8
Show member pathways
12.79 CXCL8 IL1B IL2 IL2RA IL5 RNASE3
9 12.68 CASP1 FGFR2 IL1B IL1R1 TNFRSF1A
10
Show member pathways
12.66 FGFR2 IL1B IL1R1 IL2 TNFRSF1A
11
Show member pathways
12.55 IL1B IL1R1 IL2 IL2RA IL5
12 12.38 IL1R1 IL2 IL2RA TNFRSF1A
13
Show member pathways
12.27 FGFR2 IL1B IL1R1 IL2 IL2RA IL5
14
Show member pathways
12.11 CXCL8 IL1B IL2 IL5
15 11.97 CXCL8 IL1B IL1R1 IL2
16
Show member pathways
11.92 IL1B IL1R1 IL2 IL2RA
17
Show member pathways
11.92 CASP1 CXCL8 IL1B IL2 IL2RA NLRP3
18 11.84 CXCL8 IL1B IL1R1
19 11.84 IL1B IL1R1 IL2RA IL5
20 11.82 CXCL8 IL1B IL1R1 TNFRSF1A
21
Show member pathways
11.81 IL1B IL1R1 IL2 IL2RA IL5
22 11.78 CASP1 CXCL8 IL1B
23 11.76 CXCL8 IL2 IL5
24
Show member pathways
11.69 CXCL8 IL2 IL2RA IL5
25 11.68 CASP1 CXCL8 IL1B NLRP3
26 11.63 CXCL8 IL1B IL5
27
Show member pathways
11.58 CXCL8 IL1B IL2 TNFRSF1A
28 11.55 CASP1 CXCL8 IL1B
29 11.48 IL2 IL2RA IL5
30 11.4 CXCL8 IL1B IL1R1 TNFRSF1A
31
Show member pathways
11.38 IL2 IL2RA TNFRSF1A
32 11.26 IL1B IL1R1 IL2 IL2RA IL5
33 11.24 IL1B IL2 IL5
34
Show member pathways
11.17 HNRNPAB IL2 IL2RA
35 11.17 CXCL8 IL1B IL2 IL5
36 11.17 CASP1 IL1B MEFV NLRP3
37 11.13 IL1B IL1R1 NLRP3
38 10.98 IL2 IL2RA IL5 TNFRSF1A
39 10.86 IL1B IL5
40 10.5 CASP1 IL1B

GO Terms for Wells Syndrome

Cellular components related to Wells Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 CRP CXCL8 IL1B IL2 IL5 RNASE3
2 extracellular region GO:0005576 9.36 CASP1 CRP CXCL8 FGFR2 IL1B IL1R1
3 NLRP3 inflammasome complex GO:0072559 8.96 CASP1 NLRP3

Biological processes related to Wells Syndrome according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of GTPase activity GO:0043547 9.98 FGFR2 IL2 IL2RA IL5 RACK1
2 immune response GO:0006955 9.87 CXCL8 IL1B IL1R1 IL2 IL2RA IL5
3 apoptotic process GO:0006915 9.86 CASP1 FGFR2 IL1B IL2RA NLRP3 RACK1
4 MAPK cascade GO:0000165 9.83 FGFR2 IL1B IL2 IL2RA IL5
5 response to lipopolysaccharide GO:0032496 9.81 CASP1 FGFR2 IL1B TNFRSF1A
6 cytokine-mediated signaling pathway GO:0019221 9.77 IL1B IL1R1 IL1RAPL2 IL5 TNFRSF1A
7 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.74 CASP1 NLRP3 RACK1
8 cellular response to mechanical stimulus GO:0071260 9.73 CASP1 IL1B TNFRSF1A
9 regulation of inflammatory response GO:0050727 9.71 CASP1 IL1R1 NLRP3
10 positive regulation of T cell proliferation GO:0042102 9.7 IL1B IL2 IL2RA
11 positive regulation of immunoglobulin secretion GO:0051024 9.58 IL2 IL5
12 positive regulation of ceramide biosynthetic process GO:2000304 9.55 RACK1 TNFRSF1A
13 negative regulation of inflammatory response GO:0050728 9.55 IL2 IL2RA MEFV NLRP3 TNFRSF1A
14 regulation of establishment of endothelial barrier GO:1903140 9.49 IL1B TNFRSF1A
15 negative regulation of lymphocyte proliferation GO:0050672 9.48 IL2 IL2RA
16 regulation of T cell homeostatic proliferation GO:0046013 9.46 IL2 IL2RA
17 squamous basal epithelial stem cell differentiation involved in prostate gland acinus development GO:0060529 9.4 FGFR2 TP63
18 inflammatory response GO:0006954 9.23 CRP CXCL8 IL1B IL2RA IL5 MEFV
19 interleukin-1 beta production GO:0032611 9.13 CASP1 IL1B NLRP3

Molecular functions related to Wells Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 CXCL8 IL1B IL2 IL5
2 interleukin-1 receptor activity GO:0004908 8.96 IL1R1 IL1RAPL2
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.92 FGFR2 IL2 IL2RA IL5

Sources for Wells Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48